Published in Ann Oncol on February 01, 2010
Should the prescription of oral anticancer drugs be restricted? Rep Pract Oncol Radiother (2012) 0.87
Treatment of cancer with drugs: a controversy. Ann Oncol (2011) 0.86
Treatment of thyroid cancer with the new oral agents. Ann Oncol (2011) 0.85
[Implications of modern anticancer therapies for palliative care concepts]. Schmerz (2010) 0.79
The next generation of radiation oncologists: Challenges and perspectives. Rep Pract Oncol Radiother (2012) 0.78
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology. Actas Urol Esp (2013) 0.78
Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. Cancers (Basel) (2016) 0.75
The prescription of oral anticancer drugs: Another perspective. Rep Pract Oncol Radiother (2012) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol (1997) 4.43
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Alternate endpoints for screening phase II studies. Clin Cancer Res (2009) 1.47
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2007) 1.27
Recommendations for a Global Core Curriculum in Medical Oncology. Ann Oncol (2004) 1.22
Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer (2008) 1.08
Position paper by the UKCCCR elderly cancer patients in clinical trials working group. Br J Cancer (2000) 1.07
Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat (2005) 0.94
National integration of European standards. Ann Oncol (2007) 0.90
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The EGF receptor family as targets for cancer therapy. Oncogene (2000) 5.44
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol (1998) 3.69
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene (2011) 3.59
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol (2011) 3.55
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Light intensity regulation of cab gene transcription is signaled by the redox state of the plastoquinone pool. Proc Natl Acad Sci U S A (1995) 3.19
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene (2008) 2.72
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J Thromb Haemost (2004) 2.71
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol (2003) 2.63
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization. Differentiation (1997) 2.58
Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease. J Thromb Haemost (2014) 2.52
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol (2001) 2.48
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. J Virol (1994) 2.29
Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol (1997) 2.28
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J (2010) 2.08
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol (2008) 2.06
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res (1993) 2.03
[Multimodal treatment of clinical non-small cell N2 bronchogenic carcinoma. What is the answer?]. Arch Bronconeumol (2006) 2.03
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science (1990) 2.00
Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond) (2011) 2.00
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol (2004) 1.85
Mechanism of action of trastuzumab and scientific update. Semin Oncol (2001) 1.77
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (1999) 1.74
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J (2011) 1.74
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol (2004) 1.71
Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A (2000) 1.69
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology (1998) 1.69
Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol (1989) 1.68
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol (1998) 1.68
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif (2008) 1.65
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) Ann Oncol (1999) 1.62
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res (1999) 1.59
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol (1999) 1.58
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol (2006) 1.58
[Pandemic influenza A in the ICU: experience in Spain and Latin America. GETGAG/SEMICYUC/(Spanish Working Group on Severe Pandemic Influenza A/SEMICYUC)]. Med Intensiva (2010) 1.58
Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci (1994) 1.58
PCR analysis of the cryI insecticidal crystal family genes from Bacillus thuringiensis. Appl Environ Microbiol (1994) 1.55
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2001) 1.54
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood (1997) 1.52
Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis (2001) 1.51
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol (2005) 1.51
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J (2009) 1.51
Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest (2002) 1.50
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol (2004) 1.49
Early complications of endoscopic treatment for superficial bladder tumors. J Urol (2000) 1.48
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol (2010) 1.48
Institutional declaration in favour of the development of interdisciplinary cancer care in Spain. Clin Transl Oncol (2010) 1.47
The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Cancer Res (2013) 1.47
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2013) 1.46
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol (2011) 1.46
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol (2001) 1.46
The quotient of number of nodes and tumour size (N/T) from primary breast cancer predicts the clinical course after diagnosis of distant relapse. Eur J Surg Oncol (2004) 1.44
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest (1997) 1.43
Cuban programme for prevention of sickle cell disease. Lancet (1991) 1.43
CDC group IV c-2 infection in a stem cell transplant recipient. Bone Marrow Transplant (1997) 1.43
Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clin Transl Oncol (2013) 1.42
The "El Alamo" project (1990-1997): two consecutive hospital-based studies of breast cancer outcomes in Spain. Clin Transl Oncol (2006) 1.41
Growth and growth hormone secretion in children with cancer treated with chemotherapy. J Pediatr (1997) 1.41